Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03833180 · ClinicalTrials.gov registry record · Phase 1
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
A Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 14
- Study locations
NCT03833180 is a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that has completed, run by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 91 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (50% lower). The trial reports 14 study locations across 7 states.
The verdict
NCT03833180, a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, has completed, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).
Conditions Studied
Interventions
- DRUG Zilovertamab vedotin
Study Locations (14)
New York
- Northwell Health ( Site 0009) - New Hyde Park
- Weill Cornell Medical College ( Site 0005) - New York
- Memorial Sloan Kettering Cancer Center ( Site 0014) - New York
- University of Rochester ( Site 0008) - Rochester
- Memorial Sloan-Kettering Cancer Center ( Site 0019) - Uniondale
California
- City of Hope ( Site 0010) - Duarte
- University of California - San Diego ( Site 0003) - La Jolla
- UCLA Hematology & Oncology ( Site 0007) - Los Angeles
Texas
- MD Anderson Cancer Center ( Site 0001) - Houston
- MD Anderson Cancer Center ( Site 0011) - Houston
Nebraska
- University of Nebraska Medical Center ( Site 0006) - Omaha
Oregon
- Oregon Health & Science University ( Site 0004) - Portland
Virginia
- University of Virginia Cancer Center ( Site 0012) - Charlottesville
Washington
- Swedish Medical Center ( Site 0002) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-03-14 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03833180
The ClinicalTrials.gov registry entry for NCT03833180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (50% lower). The listed sponsor is VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Zilovertamab vedotin is the first listed.
NCT03833180 reports 14 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Texas.
Frequently Asked Questions
What is clinical trial NCT03833180 about?
NCT03833180 is a clinical study titled "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)". The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid l...
What is the current status of trial NCT03833180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2019-03-14. Estimated completion is 2023-12-18.
What conditions does trial NCT03833180 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma.
What interventions are being tested in trial NCT03833180?
The interventions under investigation include: Zilovertamab vedotin (DRUG).
Who is sponsoring clinical trial NCT03833180?
This trial is sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03833180 being conducted?
This trial has 14 study locations across California, Nebraska, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Lymphocytic Leukemia
All registered trials for this condition
Diffuse Large B Cell Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.